Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 405 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Brain PET Scan Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

NCT06254469
View directory record Official record
Conditions
Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions
[F-18]Flornaptitril
Drug
Lead sponsor
CereMark Pharma, LLC
Industry
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282
View directory record Official record
Conditions
Alzheimer Disease, Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
55 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 17, 2026, 9:34 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

NCT00781482
View directory record Official record
Conditions
Healthy
Interventions
eszopiclone, zolpidem, placebo
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 17, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional Results available

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617
View directory record Official record
Conditions
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
Interventions
Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

NCT00538798
View directory record Official record
Conditions
Healthy, Glutamate Receptor, mGlur5 Protein, Excitatory Amino Acid Receptors, Drug Kinetics, PET Scan
Interventions
[18F]SP203
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 17, 2026, 9:34 AM EDT
Not listed Phase 2 Interventional

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

NCT00805636
View directory record Official record
Conditions
Brain Metastases, Solid Tumors
Interventions
2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10), Stereotactic Radio-Surgery (SRS) therapy, Positron Emission Tomography
Drug · Radiation · Procedure
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Oct 17, 2026, 9:34 AM EDT
Approved For Marketing No phase listed Expanded access

Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study

NCT02355054
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
C-11 Choline PET Imaging
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 17, 2026, 9:34 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Quantitative Imaging of Brain Glymphatic Function in Humans

NCT04768101
View directory record Official record
Conditions
Parkinson Disease
Interventions
[11C]-PIB
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
55 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 9:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Arterial Spin Labeling (ASL) MRI for Cognitive Decline

NCT01727622
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
FDG-PET, ASL-MRI, Lumbar Puncture
Drug · Other · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 89 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Early Phase 1 Interventional

Brain Dopaminergic Signaling in Opioid Use Disorders

NCT03190954
View directory record Official record
Conditions
Normal Physiology, Opioid Use Disorders
Interventions
[11C]raclopride plus placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

NCT02849171
View directory record Official record
Conditions
Brain Cancer
Interventions
PET scan, C-Choline
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 17, 2026, 9:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

NCT03372317
View directory record Official record
Conditions
Mild Cognitive Impairment, Aging
Interventions
18F-MK-6240
Drug
Lead sponsor
Yaakov Stern
Other
Eligibility
55 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Early Phase 1 Interventional

PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A

NCT01198197
View directory record Official record
Conditions
Pain, Anxiety, Depression
Interventions
NOP-1A
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 9:34 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

NCT04840979
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

NCT01540513
View directory record Official record
Conditions
Glioblastoma Multiforme, Brain Metastases
Interventions
NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 17, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Flortaucipir 18F PET Imaging in BIOCARD Study

NCT03052972
View directory record Official record
Conditions
Cognitive Decline
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 17, 2026, 9:34 AM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT01165632
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma
Interventions
biopsy, computed tomography, therapeutic conventional surgery, radiation therapy treatment planning/simulation, radiation therapy, magnetic resonance imaging, positron emission tomography, fluorine F 18 fluorodopa
Procedure · Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 17, 2026, 9:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand

NCT02056249
View directory record Official record
Conditions
Hypoglycemia
Interventions
Norepinephrine Transporter (NET) ligand
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 17, 2026, 9:34 AM EDT
Completed No phase listed Observational

Tryptophan Metabolism in Human Brain Tumors-Novocure

NCT02367482
View directory record Official record
Conditions
Glioblastoma
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 17, 2026, 9:34 AM EDT
Completed No phase listed Observational

Eye to Brain Connection

NCT05215782
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 17, 2026, 9:34 AM EDT
Not listed Phase 4 Interventional

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

NCT00937261
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Paliperidone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 17, 2026, 9:34 AM EDT